Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: SCN007
MIFTS: 51

Secondary Hyperparathyroidism

Categories: Blood diseases, Bone diseases, Cancer diseases, Endocrine diseases, Genetic diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Secondary Hyperparathyroidism

About this section

MalaCards integrated aliases for Secondary Hyperparathyroidism:

Name: Secondary Hyperparathyroidism 12 36 15 17
Hyperparathyroidism, Secondary 43
Hyperparathyroidism Secondary 54

Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases Cancer diseases
Anatomical: Endocrine diseases Bone diseases Blood diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:12466
KEGG 36 H01669
MeSH 43 D006962
NCIt 49 C113335
SNOMED-CT 67 91478007
ICD10 32 E21.1
UMLS 71 C0020503
Sources

Summaries for Secondary Hyperparathyroidism

About this section
KEGG : 36 Secondary hyperparathyroidism (SHPT) is a chronic and progressive disorder characterized by elevated serum parathyroid hormone (PTH), parathyroid gland hyperplasia, and disturbances in mineral metabolism, mainly calcium and phosphorus. SHPT is generally caused by diffuse parathyroid hyperplasia in response to prolonged reduced levels of extracellular calcium from various secondary aetiologies. Although it is initially and adaptive response to a variety of stimuli resulting mainly in extracellular hypocalcaemia (vitamin D deficiency, chronic kidney disease, idiopathic hypercalciuria, calcium malabsorption), long-standing SHPT may eventually develop into autonomous HPT (ie, tertiary HPT). Because SHPT is a compensatory mechanism of the parathyroid glands, it commonly resolves with normalization of calcium and phosphorus homeostasis. After excluding reversible secondary aetiologies, first-line treatment of irreversible SHPT (often related to chronic kidney disease) mainly involves medical therapies.

MalaCards based summary : Secondary Hyperparathyroidism, also known as hyperparathyroidism, secondary, is related to vitamin d-dependent rickets, type 2a and rickets. An important gene associated with Secondary Hyperparathyroidism is CASR (Calcium Sensing Receptor), and among its related pathways/superpathways are Mesenchymal Stem Cells and Lineage-specific Markers and Parathyroid hormone synthesis, secretion and action. The drugs Nicotinamide and Cinacalcet have been mentioned in the context of this disorder. Affiliated tissues include kidney, bone and heart, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 74 Secondary hyperparathyroidism is the medical condition of excessive secretion of parathyroid hormone... more...

Sources

Related Diseases for Secondary Hyperparathyroidism

About this section

Diseases in the Hyperparathyroidism family:

Hyperparathyroidism 1 Hyperparathyroidism 3
Hyperparathyroidism 4 Primary Hyperparathyroidism
Secondary Hyperparathyroidism Rare Hyperparathyroidism

Diseases related to Secondary Hyperparathyroidism via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 378)
# Related Disease Score Top Affiliating Genes
1 vitamin d-dependent rickets, type 2a 32.4 VDR CYP27B1
2 rickets 31.5 VDR PTH KL GC FGF23 CYP27B1
3 end stage renal disease 31.5 PTH FGF23 EPO ALB
4 calcinosis 31.0 KL FGF23 CALCA
5 hyperphosphatemia 31.0 VDR TNFRSF11B PTH KL FGF23 CASR
6 pseudohypoparathyroidism 30.8 PTH CALCA BGLAP
7 hypercalcemia, infantile, 1 30.8 VDR PTH CASR CALCA
8 deficiency anemia 30.8 PTH FGF23 EPO ALB
9 parathyroid carcinoma 30.7 PTH MEN1 CASR CALCA
10 graves disease 1 30.7 PTH CALCA ALB
11 metabolic acidosis 30.6 PTH FGF23 BGLAP ALB
12 osteitis fibrosa 30.6 PTH FGF23 CASR CALCA BGLAP B2M
13 calciphylaxis 30.6 VDR PTH FGF23 EPO CASR ALB
14 hypophosphatemic rickets, x-linked recessive 30.6 VDR FGF23 CYP27B1
15 familial hypocalciuric hypercalcemia 30.5 PTH MEN1 CXADR CASR
16 hyperparathyroidism 2 with jaw tumors 30.5 MEN1 CASR
17 hyperparathyroidism, neonatal severe 30.4 NR1I3 CXADR CASR
18 urolithiasis 30.4 VDR CASR BGLAP ALB
19 idiopathic hypercalciuria 30.4 VDR SLPI NR1I3 CASR BGLAP
20 oncogenic osteomalacia 30.4 PTH FGF23
21 chronic pyelonephritis 30.3 CALCA B2M ALB
22 primary hyperparathyroidism 30.3 VDR TNFRSF11B PTH NR1I3 MEN1 KL
23 nephrocalcinosis 30.3 PTH FGF23 CASR ALB
24 thyroid gland disease 30.3 PTH CALCA ALB
25 uremia 30.3 VDR TNFRSF11B PTH MEN1 EPO CASR
26 hypoparathyroidism 30.3 VDR PTH NR1I3 FGF23 CXADR CASR
27 bone resorption disease 30.2 VDR TNFRSF11B PTH FGF23 CASR CALCA
28 parathyroid adenoma 30.2 VDR PTH MEN1 CXADR CASR CALCA
29 hyperthyroidism 30.2 PTH CALCA BGLAP ALPP ALB ACP5
30 hypocalciuric hypercalcemia, familial, type i 30.1 PTH CASR
31 familial tumoral calcinosis 30.1 KL FGF23
32 sclerosteosis 30.1 VDR TNFRSF11B PTH BGLAP
33 osteomalacia 30.0 VDR PTH GC FGF23 CYP27B1 CASR
34 hyperostosis 30.0 TNFRSF11B KL FGF23
35 kidney disease 30.0 VDR TNFRSF11B SLPI PTH FGF23 EPO
36 mccune-albright syndrome 30.0 MEN1 FGF23 BGLAP ALPP
37 mammary paget's disease 30.0 TNFRSF11B PTH CALCA BGLAP ACP5
38 hyperparathyroidism 30.0 VDR TNFRSF11B SLPI PTH NR1I3 MEN1
39 taqi polymorphism 30.0 VDR TGFA
40 renal osteodystrophy 29.9 VDR TNFRSF11B SLPI PTH FGF23 EPO
41 hypophosphatemic rickets, x-linked dominant 29.9 PTH KL FGF23 CYP27B1
42 osteonecrosis 29.9 TNFRSF11B PTH BGLAP ACP5
43 spondyloarthropathy 1 29.8 TNFRSF11B PTH BGLAP B2M
44 hypophosphatemia 29.8 VDR PTH KL FGF23 CYP27B1 BGLAP
45 polycystic kidney disease 29.8 KL FGF23 EPO ALB
46 polyneuropathy 29.6 EPO CALCA B2M ALB
47 myelofibrosis 29.5 TNFRSF11B PTH EPO ACP5
48 glucocorticoid-induced osteoporosis 29.5 VDR TNFRSF11B PTH CALCA BGLAP ACP5
49 bone disease 29.2 VDR TNFRSF11B SLPI PTH NR1I3 FGF23
50 hypocalcemia, autosomal dominant 1 29.2 VDR PTH NR1I3 FGF23 CYP27B1 CXADR

Graphical network of the top 20 diseases related to Secondary Hyperparathyroidism:



Diseases related to Secondary Hyperparathyroidism
Sources

Symptoms & Phenotypes for Secondary Hyperparathyroidism

About this section

GenomeRNAi Phenotypes related to Secondary Hyperparathyroidism according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00106-A-0 9.64 MEN1
2 Decreased viability GR00221-A-1 9.64 NR1I3 TNFRSF11B
3 Decreased viability GR00221-A-2 9.64 NR1I3 TNFRSF11B
4 Decreased viability GR00249-S 9.64 ACP5 ALB NR1I3 TNFRSF11B
5 Decreased viability GR00301-A 9.64 NR1I3 TGFA
6 Decreased viability GR00381-A-1 9.64 CALCA SLPI
7 Decreased viability GR00386-A-1 9.64 ALB B2M EPO KL NR1I3 VDR
8 Decreased viability GR00402-S-2 9.64 CXADR TNFRSF11B

MGI Mouse Phenotypes related to Secondary Hyperparathyroidism:

45 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.32 ALB B2M BGLAP CASR CXADR CYP27B1
2 cardiovascular system MP:0005385 10.3 ALB B2M CXADR EPO FGF23 GC
3 endocrine/exocrine gland MP:0005379 10.27 ALB B2M BGLAP CASR CXADR CYP27B1
4 homeostasis/metabolism MP:0005376 10.25 ALB B2M BGLAP CASR CXADR CYP27B1
5 immune system MP:0005387 10.24 ALB B2M BGLAP CASR CXADR CYP27B1
6 hematopoietic system MP:0005397 10.21 B2M BGLAP CASR CXADR CYP27B1 EPO
7 digestive/alimentary MP:0005381 10.13 ALB B2M CASR CXADR FGF23 KL
8 mortality/aging MP:0010768 10.07 ALB B2M CASR CXADR EPO FGF23
9 craniofacial MP:0005382 10.04 CYP27B1 KL MEN1 PTH TGFA TNFRSF11B
10 limbs/digits/tail MP:0005371 9.87 CYP27B1 EPO FGF23 KL PTH TNFRSF11B
11 muscle MP:0005369 9.76 ALB CASR CXADR EPO KL MEN1
12 reproductive system MP:0005389 9.61 B2M BGLAP CYP27B1 FGF23 KL MEN1
13 skeleton MP:0005390 9.36 BGLAP CASR CYP27B1 EPO FGF23 GC
Sources

Drugs & Therapeutics for Secondary Hyperparathyroidism

About this section

Drugs for Secondary Hyperparathyroidism (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 102)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
2
Cinacalcet Approved Phase 4 226256-56-0 156419
3
tannic acid Approved Phase 4 1401-55-4
4
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
5
Calcium carbonate Approved, Investigational Phase 4 471-34-1
6
Darbepoetin alfa Approved, Investigational Phase 4 11096-26-7, 209810-58-2
7
Alendronate Approved Phase 4 66376-36-1, 121268-17-5 2088
8
Atorvastatin Approved Phase 4 134523-00-5 60823
9
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
10
Angiotensin II Approved, Investigational Phase 4 4474-91-3, 11128-99-7, 68521-88-0 172198
11
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
12
Racepinephrine Approved Phase 4 329-65-7 838
13
Ethanol Approved Phase 4 64-17-5 702
14
Iron Approved, Experimental Phase 4 15438-31-0, 7439-89-6 27284 23925
15
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
16
Niacin Approved, Investigational, Nutraceutical Phase 4 59-67-6 938
17
Alfacalcidol Approved, Nutraceutical Phase 4 41294-56-8 5282181
18
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 22737-96-8, 68-26-8, 11103-57-4 9904001 445354
19
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 5280795 6221
20
Calcitriol Approved, Nutraceutical Phase 4 32222-06-3 5280453 134070
21 Vitamin B Complex Phase 4
22 Vitamin B3 Phase 4
23 Nicotinic Acids Phase 4
24 Vasodilator Agents Phase 4
25 Folate Phase 4
26 Vitamin B9 Phase 4
27 Hormone Antagonists Phase 4
28 Pharmaceutical Solutions Phase 4
29 Antacids Phase 4
30 Anti-Ulcer Agents Phase 4
31 Gastrointestinal Agents Phase 4
32 Hematinics Phase 4
33 Antihypertensive Agents Phase 4
34 Lipid Regulating Agents Phase 4
35 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
36 Anticholesteremic Agents Phase 4
37 Hypolipidemic Agents Phase 4
38 Antimetabolites Phase 4
39 Angiotensin II Type 1 Receptor Blockers Phase 4
40 Angiotensinogen Phase 4
41 Angiotensin Receptor Antagonists Phase 4
42 Giapreza Phase 4
43 Epinephryl borate Phase 4
44 Antioxidants Phase 4
45 Butylated Hydroxytoluene Phase 4
46 Antibodies Phase 4
47 Immunoglobulins, Intravenous Phase 4
48 Immunoglobulin A Phase 4
49 Immunoglobulins Phase 4
50 Retinol palmitate Phase 4

Interventional clinical trials:

(show top 50) (show all 251)
# Name Status NCT ID Phase Drugs
1 Providing Intravenous Paricalcitol Treatment to the Sick and Poor Chronic Hemodialysis Patients With Severe Secondary Hyperparathyroidism Resistant to Existing Vitamin D Analogs Unknown status NCT03023748 Phase 4 Intravenous Paricalcitol
2 An Open-label Study of Combination of Cinacalcet and Active Vitamin D Analogue in the Management of Severe Secondary Hyperparathyroidism in Haemodialysis Patients Unknown status NCT02338934 Phase 4 Combination Cinacalcet with Vitamin D analogue
3 Additive Renoprotective Effects of Oral Calcitriol in Nondiabetic Chronic Kidney Disease Patients Unknown status NCT01512862 Phase 4 Calcitriol;Placebo
4 Regulation of Bone Mineralization in Renal Osteodystrophy Unknown status NCT01799317 Phase 4 Vitamin D2
5 The Efficacy and Safety of Niacin on Hyperphosphatemia in End Stage Renal Disease Patients Undergoing Haemodialysis Unknown status NCT03163576 Phase 4 Niacin;Phosphate Binder
6 Study of Vitamin D2 Virus 1,25(OH)2-Vitamin D3 and Normal Protein Diet Virus Low Protein Diet in the Treatment of CKD-MBD and Malnutrition for Progressive CKD Patients Unknown status NCT02005302 Phase 4 1,25(OH)2 Vitamin D3;Vitamin D2
7 A Phase IV, Single-Center, Active-Controlled Cross-Over Pilot Study to Evaluate the Effects of Zemplar Injection and Calcijex on Intestinal Absorption of Calcium Completed NCT00073710 Phase 4 Zemplar;Calcijex
8 Safety and Effectiveness of Zemplar Injection in Decreasing iPTH Levels in Pediatric ESRD Subjects on Hemodialysis Completed NCT00053547 Phase 4 paricalcitol injection
9 Randomized Trial to Evaluate the Efficacy and Safety of Cinacalcet Treatment in Combination With Low Dose Vitamin D for the Treatment of Subjects With Secondary Hyperparathyroidism (SHPT) Recently Initiating Hemodialysis Completed NCT00803712 Phase 4 Cinacalcet;Vitamin D
10 A Phase 4, Multi Center, Open-Label, Randomized Study to Determine Clinically Appropriate Doses of Hectorol® (Doxercalciferol Capsules) When Converting From Zemplar® (Paricalcitol Injection) for the Treatment of Secondary Hyperparathyroidism in Stage 5 Chronic Kidney Disease (CKD) Subjects on Hemodialysis. Completed NCT00463021 Phase 4 Hectorol (doxercalciferol capsules);Zemplar (paricalcitol injection)
11 A Multi-center Study Evaluating Efficacy and Safety of Cinacalcet Hydrochloride(HCL) in Calcium, Phosphorus and Intact Parathyroid Hormone(iPTH) Serum Levels in Chinese Chronic Kidney Disease(CKD) Hemodialysis(HD) Patients With Mild, Moderate and Severe Secondary Hyperparathyroidism(SHPT) Completed NCT03123406 Phase 4 Cinacalcet HCl
12 A Randomized , Open-Label, Cross-over, Pharmacokinetic Study of Doxercalciferol and Paricalcitol Following Multiple Intravenous Injections in Chronic Kidney Disease Subjects on Hemodialysis Completed NCT00454350 Phase 4 Hectorol (doxercalciferol injection);Zemplar (Paricalcitol injection)
13 Prospective, Non-randomized, Multicenter Study to Assess the Efficacy and Safety of Oral or Intravenous Paricalcitol Administered Over 6 Months to Patients With Secondary Hyperparathyroidism on Dialysis Completed NCT00537979 Phase 4 Paricalcitol injection;Paricalcitol capsules
14 Phase 4 Study of Cinacalcet Efficacy in Combination With Vitamin D for the Treatment of Secondary Hyperparathyroidism in Peritoneal Dialysis Patients Completed NCT01101113 Phase 4 cinacalcet;control
15 ACHIEVE: Optimizing the Treatment of Secondary Hyperparathyroidism: A Comparison of Sensipar® and Low Dose Vitamin D vs. Escalating Doses of Vitamin D Alone Completed NCT00135304 Phase 4 Sensipar®;Vitamin D
16 A Phase 4, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Study to Assess the Efficacy and Safety of Doxercalciferol Capsules in Vitamin D-replete Subjects With Chronic Kidney Disease (CKD) Stages 3 or 4 With Secondary Hyperparathyroidism (SHPT). Completed NCT00123461 Phase 4 Hectorol (doxercalciferol capsules), 0.5mcg
17 Efficacy and Safety of Paricalcitol in the Reduction of Secondary Hyperparathyroidism After Renal Transplantation. Completed NCT01939977 Phase 4 Paricalcitol;Calcifediol
18 A Multicenter, Randomized, Open Label Study to Compare the Efficacy of Cinacalcet Versus Traditional Vitamin D Therapy for Management of Secondary Hyperparathyroidism Among Subjects Undergoing Hemodialysis Completed NCT01181531 Phase 4 Traditional Vitamin D Therapy;Cinacalcet
19 A Study To Assess Achievement of NKF K/DOQI Targets Using Sensipar (Cinacalcet) in Australian Subjects With End Stage Renal Disease (ESRD) Who Are Being Treated With Aranesp for Anaemia Management Completed NCT00431496 Phase 4 Cinacalcet
20 A Prospective, Non-randomised, Single-arm, Open-Label Pilot Clinical Study Evaluating the Effect of PTH Lowering on Erythropoietin Consumption in Calcitriol-Resistant Patients Completed NCT01506947 Phase 4 Paricalcitol;Darbepoetin alfa
21 A Phase 4, Multi-Center, Open-Label, Randomized Study to Determine Clinically Appropriate Doses of Hectorol® Capsules When Converting From Hectorol® Injection for the Treatment of SHPT in Stage 5 CKD Subjects on Hemodialysis Completed NCT00418600 Phase 4 Hectorol® (doxercalciferol capsules);doxercalciferol capsules, Hectorol®;doxercalciferol capsules, Hectorol® capsules
22 Initial Dosing of Paricalcitol Based on iPTH Parathyroid Hormone Levels in Hemodialysis Patients With Secondary Hyperparathyroidism Completed NCT00307840 Phase 4 paricalcitol
23 A Randomized Trial Comparing Pulse Calcitriol and Alfacalcidol for the Treatment of Secondary Hyperparathyroidism in Hemodialysis Patients Completed NCT01115543 Phase 4 alfacalcidol and calcitriol
24 Effect of Cinacalcet Treatment on Vascular Arterial Stiffness Among Peritoneal Dialysis Patients With Secondary Hyperparathyroidism Completed NCT01143987 Phase 4 Cinacalcet
25 A Phase 4 Randomized Multicenter Open Label Trial of Paricalcitol Versus Calcitriol for Efficacy and Safety in Stage 3 or 4 Ckd Patients With Secondary Hyperparathyroidism Completed NCT00823303 Phase 4 Paricalcitol;Calcitriol
26 A Prospective, Randomized Trial to Compare Subtotal Parathyroidectomy Versus Cinacalcet in the Treatment of Persistent Secondary Hyperparathyroidism Post Renal Transplantation Completed NCT01178450 Phase 4 Cinacalcet
27 Sensipar Treatment Algorithm to Reach K/DOQI Targets in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism Completed NCT00132431 Phase 4 Sensipar
28 Effectiveness and Safety of a 6-Month Treatment With IV Zemplar in Patients on Hemodialysis and With Secondary Hyperparathyroidism Using iPTH/100 as Initial Dose Completed NCT00891813 Phase 4 Zemplar (paricalcitol)
29 The IMPACT SHPT Study: Study to Evaluate the Improved Management of iPTH With Paricalcitol-centered Therapy vs. Cinacalcet Therapy With Low-dose Vitamin D in Hemodialysis Patients With Secondary Hyperparathyroidism Completed NCT00977080 Phase 4 Paricalcitol;Cinacalcet
30 Response of Secondary Hyperparathyroidism to Paricalcitol Versus Ergocalciferol in Patients With Stage 3 and 4 Chronic Kidney Disease With Vitamin D Deficiency: a Randomized Controlled Trial Completed NCT00958451 Phase 4 Paricalcitol;Ergocalciferol
31 The Study of Efficacy and Safety of Calcium Sensing Receptor in Chronic Dialysis Patients Completed NCT02056730 Phase 4 calcium sensing receptor agonist
32 Effect of Doxercalciferol on Endothelial Cell Function in End Stage Renal Disease Completed NCT00528788 Phase 4 doxercalciferol
33 Characterization of Hyperparathyroidism and Vitamin D Deficiency in Obesity Completed NCT00288873 Phase 4 Ergocalciferol;Cholecalciferol
34 Trial to Optimize Mineral Outcomes in End Stage Renal Disease (ESRD) Patients Completed NCT01100723 Phase 4
35 A Phase 4, Single-Center, Open-Label, Randomized, Active-Controlled, Cross-over Pilot Study to Evaluate the Effects of Two Vitamin D Analogs, Zemplar® Injection and Hectorol® Injection, on Intestinal Absorption of Calcium in CKD Stage 5 Subjects on Hemodialysis Completed NCT00257920 Phase 4 Zemplar® injection;Hectorol® injection
36 Effect of Etelcalcetide on Cardiac Hypertrophy in Hemodialysis Patients: A Randomized Controlled Trial Completed NCT03182699 Phase 4
37 A Randomized Study to Evaluate the Effects of Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease (CKD) Receiving Hemodialysis Completed NCT00379899 Phase 4 cinacalcet
38 Efficacy of a Calcimimetic (Cinacalcet) in the Long Term Control of Patients With Primary Hyperparathyroidism Completed NCT02417389 Phase 4 cinacalcet;Alendronate
39 CARE-2 (Calcium Acetate (PhosLo®)/Sevelamer(Renagel®) Evaluation Study 2) Completed NCT00211939 Phase 4 calcium acetate;sevelamer;atorvastatin
40 Vitamin D Status in Males in Jerusalem Area and Its Correlation to Parathyroid Hormone (PTH) Level and Bone Mineral Density Completed NCT01025128 Phase 4 25 OH vitamin D
41 An Open-Label, Randomised Study Using Cinacalcet to Improve Achievement of Kidney Disease Outcomes Quality Initiative (K/DOQI) Targets in Patients With ESRD Completed NCT00110890 Phase 4 cinacalcet
42 Physiologic Interactions Between the Adrenal- and the Parathyroid Glands Completed NCT02572960 Phase 4 Valsartan;Placebo Valsartan
43 A Randomized Trial Comparing an Integrated Care Approach Using Electronic Cinacalcet Adherence Data Versus Usual Care to Improve Secondary Hyperparathyroidism in Hemodialysis Patients Completed NCT01573520 Phase 4
44 Effect of Phosphate Binders on FGF-23 During Calcitriol Administration in CKD Stage 3 Patients Completed NCT01748396 Phase 4 Calcitriol;Calcium Carbonate
45 A Pilot Study to Evaluate the Efficacy of Total Parathyroidectomy in Retarding Cardiovascular Calcification in End-stage Renal Disease Patients Completed NCT00745719 Phase 4
46 A Phase IV, Randomized, Single-center Study of the Effects of Calcitriol and Paricalcitol on Vascular Calcification in Chronic Kidney Disease Stages 3 and 4 Completed NCT00752102 Phase 4 Calcitriol (Rocaltrol®);Paricalcitol
47 Direct Effect of Paricalcitol on Anemia in Chronic Kidney Disease Completed NCT01768351 Phase 4 Paricalcitol;Calcitriol
48 Study of Vitamin D2 Virus 1,25(OH)2-Vitamin D3 in the Treatment of Chronic Kidney Disease Mineral and Bone Disease Completed NCT01633853 Phase 4 Vitamin D2;1,25(OH)2 Vit D3
49 Randomised Controlled Trial of the Effect of Alendronate on Vascular Calcification and Arterial Stiffness in Chronic Kidney Disease: A Pilot Study Completed NCT00395382 Phase 4 Alendronate;Placebo
50 Randomized Clinical Trial for The Evaluation of The Effects Of Cholecalciferol Supplementation On The Parathyroid Hormone In Hemodialysis Patients Completed NCT03648528 Phase 4 cholecalciferol;placebo

Search NIH Clinical Center for Secondary Hyperparathyroidism

Cochrane evidence based reviews: hyperparathyroidism, secondary

Sources

Genetic Tests for Secondary Hyperparathyroidism

About this section
Sources

Anatomical Context for Secondary Hyperparathyroidism

About this section

MalaCards organs/tissues related to Secondary Hyperparathyroidism:

40
Kidney, Bone, Heart, Thyroid, Liver, Breast, Prostate
Sources

Publications for Secondary Hyperparathyroidism

About this section

Articles related to Secondary Hyperparathyroidism:

(show top 50) (show all 6751)
# Title Authors PMID Year
1
Roles of calcium-sensing receptor and vitamin d receptor in the pathophysiology of secondary hyperparathyroidism. 61 54
20303786 2010
2
The fibroblast growth factor 23: a new player in the field of cardiovascular, bone and renal disease. 54 61
20180772 2010
3
Persistent secondary hyperparathyroidism and vertebral fractures in kidney transplantation: role of calcium-sensing receptor polymorphisms and vitamin D deficiency. 61 54
19839774 2010
4
Physiology and pathophysiology of the calcium-sensing receptor in the kidney. 61 54
19923405 2010
5
Control of secondary hyperparathyroidism by vitamin D receptor agonists in chronic kidney disease. 61 54
20133492 2010
6
Depressed expression of Klotho and FGF receptor 1 in hyperplastic parathyroid glands from uremic patients. 61 54
19890272 2010
7
FGF23-parathyroid interaction: implications in chronic kidney disease. 54 61
20010546 2010
8
Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD. 61 54
19965548 2010
9
Calcium-sensing receptor as a potential modulator of vascular calcification in chronic kidney disease. 61 54
20091482 2010
10
The role of vitamin D receptor activation in chronic kidney disease. 54 61
20411052 2010
11
Clinical relevance of FGF-23 in chronic kidney disease. 54 61
19946326 2009
12
Potential for vitamin D receptor agonists in the treatment of cardiovascular disease. 61 54
19371337 2009
13
The clinical significance of parathyroid tissue calcium sensing receptor gene polymorphisms and expression levels in end-stage renal disease patients. 61 54
19640368 2009
14
Effects of calcimimetic on vascular calcification and atherosclerosis in uremic mice. 54 61
19303957 2009
15
Emerging topics in pediatric bone and mineral disorders 2008. 61 54
19615558 2009
16
Reduced relative lymphocyte count in african-americans with decompensated heart failure. 61 54
19174692 2009
17
Calcimimetics in the chronic kidney disease-mineral and bone disorder. 54 61
19363783 2009
18
Relationship between plasma fibroblast growth factor-23 concentration and bone mineralization in children with renal failure on peritoneal dialysis. 61 54
19050056 2009
19
New acquisitions in therapy of secondary hyperparathyroidism in chronic kidney disease and peritoneal dialysis patients: role of vitamin D receptor activators. 54 61
19494617 2009
20
Importance of vitamin D receptor activation in clinical practice. 61 54
19494616 2009
21
Serum fibroblast growth factor-23 levels in chronic haemodialysis patients. 61 54
18839328 2009
22
Stimulating parathyroid cell proliferation and PTH release with phosphate in organ cultures obtained from patients with primary and secondary hyperparathyroidism for a prolonged period. 61 54
19194773 2009
23
Intravenous calcitriol therapy in an early stage prevents parathyroid gland growth. 54 61
18515308 2008
24
Activator protein 2alpha mediates parathyroid TGF-alpha self-induction in secondary hyperparathyroidism. 54 61
18579641 2008
25
Vitamin D receptor ligand therapy in chronic kidney disease. 54 61
18826852 2008
26
Allosteric modulators of the human calcium-sensing receptor: structures, sites of action, and therapeutic potentials. 54 61
18782015 2008
27
Endothelial dysfunction and chronic kidney disease: treatment options. 54 61
18729004 2008
28
[Altered calcium-phosphorus metabolism and low-protein diet]. 54 61
18828130 2008
29
Cost-effectiveness of early versus late cinacalcet treatment in addition to standard care for secondary renal hyperparathyroidism in the USA. 54 61
18494747 2008
30
Does vitamin D receptor and calcium receptor activation therapy play a role in the histopathologic alterations of parathyroid glands in refractory uremic hyperparathyroidism? 61 54
18322048 2008
31
Cellular and molecular mechanisms involved in the action of vitamin D analogs targeting vitiligo depigmentation. 54 61
18393827 2008
32
Postprandial mineral metabolism and secondary hyperparathyroidism in early CKD. 54 61
18216315 2008
33
EGFR activation increases parathyroid hyperplasia and calcitriol resistance in kidney disease. 61 54
18216322 2008
34
Hypovitaminosis D and parathyroid hormone response in the elderly: effects on bone turnover and mortality. 61 54
17854393 2008
35
(2S,2'R)-analogue of LG190178 is a major active isomer. 61 54
18054230 2008
36
The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism. 61 54
18178780 2008
37
[Basic and clinical aspects of calcimimetics. Calcimimetics and vascular calcification]. 61 54
18175878 2008
38
Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis. 61 54
17914251 2008
39
Early lethality in Hyp mice with targeted deletion of Pth gene. 61 54
17615144 2007
40
Effect of cinacalcet hydrochloride, a new calcimimetic agent, on the pharmacokinetics of dextromethorphan: in vitro and clinical studies. 54 61
17652181 2007
41
Allosteric modulation of the calcium-sensing receptor. 61 54
19305800 2007
42
Vitamin D receptor: a highly versatile nuclear receptor. 61 54
17653231 2007
43
Improvement of anemia after parathyroidectomy in Chinese patients with renal failure undergoing long-term dialysis. 61 54
17638802 2007
44
Role of fibroblast growth factor 23 in phosphate homeostasis and pathogenesis of disordered mineral metabolism in chronic kidney disease. 61 54
17635819 2007
45
Vitamin D receptor agonists as anti-inflammatory agents. 61 54
20477154 2007
46
The calcimimetic R-568 increases vitamin D receptor expression in rat parathyroid glands. 54 61
17200160 2007
47
The potential for vitamin D receptor activation in cardiovascular research. 54 61
17371189 2007
48
Incidence and risk factors of coronary artery disease in patients on chronic hemodialysis. 61 54
17417765 2007
49
Clinical lessons from the calcium-sensing receptor. 61 54
17237839 2007
50
Possible influence of vitamin D receptor gene polymorphisms on recombinant human erythropoietin requirements in dialysis patients. 61 54
17275471 2007
Sources

Variations for Secondary Hyperparathyroidism

About this section
Sources

Expression for Secondary Hyperparathyroidism

About this section
Search GEO for disease gene expression data for Secondary Hyperparathyroidism.
Sources

Pathways for Secondary Hyperparathyroidism

About this section

Pathways related to Secondary Hyperparathyroidism according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Mesenchymal Stem Cells and Lineage-specific Markers 64
11.59 PTH BGLAP ALPP
2
Parathyroid hormone synthesis, secretion and action 36
11.53 VDR PTH KL FGF23 CYP27B1 CASR
3
Endocrine and other factor-regulated calcium reabsorption 36
11.3 VDR PTH KL
4
Development_Hedgehog and PTH signaling pathways in bone and cartilage development 22
11.14 VDR PTH BGLAP
5
Nuclear Receptors in Lipid Metabolism and Toxicity 1
11.04 VDR NR1I3 CYP27B1
6
Transcription_Role of VDR in regulation of genes involved in osteoporosis 22
10.75 VDR TNFRSF11B PTH CYP27B1 CALCA BGLAP
7
Osteoblast Signaling 1
10.7 TNFRSF11B PTH FGF23 BGLAP
8
Osteoclast Signaling 1
10.66 TNFRSF11B ACP5
9
Vitamin D Metabolism 1
10.46 VDR PTH GC CYP27B1
Sources

GO Terms for Secondary Hyperparathyroidism

About this section

Cellular components related to Secondary Hyperparathyroidism according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.77 TNFRSF11B TGFA SLPI PTH KL GC
2 endoplasmic reticulum lumen GO:0005788 9.55 MEN1 FGF23 BGLAP B2M ALB
3 extracellular space GO:0005615 9.4 TNFRSF11B TGFA SLPI PTH KL GC

Biological processes related to Secondary Hyperparathyroidism according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.91 TNFRSF11B TGFA PTH BGLAP B2M
2 MAPK cascade GO:0000165 9.9 TGFA MEN1 KL FGF23
3 aging GO:0007568 9.88 KL EPO CALCA BGLAP
4 response to lipopolysaccharide GO:0032496 9.86 SLPI EPO CYP27B1 ACP5
5 skeletal system development GO:0001501 9.83 VDR TNFRSF11B PTH BGLAP
6 ossification GO:0001503 9.79 CASR BGLAP ACP5
7 cellular protein metabolic process GO:0044267 9.77 MEN1 FGF23 CALCA B2M ALB
8 cellular calcium ion homeostasis GO:0006874 9.76 VDR PTH CASR CALCA
9 calcium ion homeostasis GO:0055074 9.65 PTH KL CYP27B1
10 negative regulation of bone resorption GO:0045779 9.61 TNFRSF11B CALCA
11 decidualization GO:0046697 9.61 VDR MEN1 CYP27B1
12 response to magnesium ion GO:0032026 9.59 TNFRSF11B FGF23
13 response to fibroblast growth factor GO:0071774 9.58 PTH CASR
14 regulation of bone mineralization GO:0030500 9.58 FGF23 CYP27B1 BGLAP
15 phosphate ion homeostasis GO:0055062 9.57 PTH FGF23
16 response to estrogen GO:0043627 9.56 TNFRSF11B EPO CYP27B1 BGLAP
17 positive regulation of MAPKKK cascade by fibroblast growth factor receptor signaling pathway GO:0090080 9.55 KL FGF23
18 negative regulation of calcium ion transport into cytosol GO:0010523 9.54 EPO CALCA
19 response to vitamin D GO:0033280 9.5 PTH CYP27B1 BGLAP
20 vitamin D catabolic process GO:0042369 9.49 FGF23 CYP27B1
21 cellular response to vitamin D GO:0071305 9.33 FGF23 CASR BGLAP
22 positive regulation of vitamin D 24-hydroxylase activity GO:0010980 9.13 VDR FGF23 CYP27B1
23 vitamin D metabolic process GO:0042359 8.92 VDR GC FGF23 CYP27B1

Molecular functions related to Secondary Hyperparathyroidism according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor activity GO:0038023 9.46 VDR TNFRSF11B NR1I3 CASR
2 hormone activity GO:0005179 9.26 PTH KL EPO CALCA
3 vitamin D binding GO:0005499 8.8 VDR KL GC
Sources

Sources for Secondary Hyperparathyroidism

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....